Paperpal Prime Logo

Atherosclerosis : Impact Factor & More

eISSN: 1879-1484pISSN: 0021-9150

Aims and Scope of Atherosclerosis

Atherosclerosis is a monthly peer-reviewed scientific journal established in 1970 and published by Elsevier. It is the official journal of the European Atherosclerosis Society and is affiliated with the International Atherosclerosis Society. Less

Key Metrics

CiteScore
8.7
Eigenfactor
0.01 - 0.05
H-Index
186
Impact Factor
5 - 10
SJR
Q1Cardiology and Cardiovascular Medicine
SNIP
1.45
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Atherosclerosis

Atherosclerosis Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher ELSEVIER IRELAND LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1961
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Atherosclerosis ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Atherosclerosis

The adventitia, vascular inflammation, and the intersection of hypertension and vascular disease.
  • 2 Aug 2026
  • Atherosclerosis
Therapeutic targets for atherosclerotic coronary artery disease: druggable genome-wide Mendelian randomization analysis.
  • 1 Aug 2026
  • Atherosclerosis
Dietary vitamin K intakes and atherosclerotic cardiovascular disease incidence: Findings from the UK biobank.
  • 1 Aug 2026
  • Atherosclerosis
Earliest age to detect lifetime cardiometabolic health stratification in children.
  • 1 Aug 2026
  • Atherosclerosis
Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.
  • 1 Aug 2026
  • Atherosclerosis
Serial OCT-based coronary physiology and plaque composition in vessels with nonobstructive coronary lesions following intensive lipid-lowering therapy: YELLOW III sub-study.
  • 1 Aug 2026
  • Atherosclerosis
The adventitia, vascular inflammation, and the intersection of hypertension and vascular disease.
  • 2 Aug 2026
  • Atherosclerosis
Therapeutic targets for atherosclerotic coronary artery disease: druggable genome-wide Mendelian randomization analysis.
  • 1 Aug 2026
  • Atherosclerosis
Dietary vitamin K intakes and atherosclerotic cardiovascular disease incidence: Findings from the UK biobank.
  • 1 Aug 2026
  • Atherosclerosis
Earliest age to detect lifetime cardiometabolic health stratification in children.
  • 1 Aug 2026
  • Atherosclerosis
Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.
  • 1 Aug 2026
  • Atherosclerosis
Serial OCT-based coronary physiology and plaque composition in vessels with nonobstructive coronary lesions following intensive lipid-lowering therapy: YELLOW III sub-study.
  • 1 Aug 2026
  • Atherosclerosis

FAQs on Atherosclerosis